echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > No need to consider pD-L1 expression 100-time Meisquibo inhibitors approved.

    No need to consider pD-L1 expression 100-time Meisquibo inhibitors approved.

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Bristol Myers Squibb (BMS) has announced that its heavy PD-1 inhibitor Opdivo (nivolumab) has been approved by the U.S. FDA to treat patients with advanced, recurrent or metastatic esophagus squamous cell cancer (ESCC) who are not removable after chemotherapy with fluoroureandi and platinum drugs, regardless of tumor PD-L1 expression levels.
    esophageal cancer is a type of digestive tract tumor that starts in the esophagus and grows continuously.
    cancer caused by the normal lining of the mucous membrane squamous cell carcinoma is called squamous cell carcinoma.
    for about 25 percent of patients, the disease is diagnosed at a late stage, when the patient's treatment options are very limited.
    approval is based on the results of Phase 3 clinical trial ATTRACTION-3, in which Opdivo (n-210) showed better overall survival (OS) than sequoia chemotherapy (n-209) (HR-0.77; 95% CI:0.62 to 0.96; p-0.0189).
    the median OS in the Opdivo group was 10.9 months (95% CI: 9.2-13.3), and the Dosita or Yewol group was 8.4 months (95% CI: 7.2-9.9).
    "Many cases of esophageal cancer are diagnosed at a later stage and have a significant impact on the patient's health."
    treatment options are limited as soon as patients with advanced esophageal squamous cell carcinoma progress," said Dr. Adam Lenkowsky, head of cardiovascular oncology immunology at Persimmon, "Opdivo is approved as a new therapeutic option for patients with advanced advanced esophageal squamous cell carcinoma, regardless of their PD-L1 expression, highlighting our commitment to providing new options to address unmet patient needs and taking us closer to understanding the full potential of gastrointestinal treatment."
    " original title: Express , regardless of PD-L1 expression, 100-day-mecone Squibb PD-1 inhibitor searly was approved for the treatment of advanced esophageal squamous cell carcinoma.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.